Core Viewpoint - BioPorto A/S will present its financial results for the first half of 2025 during an investor webcast scheduled for August 15, 2025 [1] Company Overview - BioPorto A/S is an in vitro diagnostics company focused on improving patient management through actionable biomarkers [2] - The company specializes in antibody and assay development, aiming to address significant unmet medical needs with its product pipeline [2] Key Products - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [3] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention [3] Market Presence - BioPorto has facilities located in Copenhagen, Denmark, and Boston, MA, USA, and its shares are listed on the Nasdaq Copenhagen stock exchange [4]

Core Viewpoint - BioPorto A/S is set to present its financial results for Q1 2025 during a webcast on May 8, 2025, highlighting its focus on early detection of Acute Kidney Injury (AKI) [1] Company Overview - BioPorto A/S specializes in in vitro diagnostics aimed at improving early detection of AKI, utilizing actionable biomarkers to enhance patient management [2][3] - The company leverages its expertise in antibodies and assay development to create innovative products addressing significant unmet medical needs [2] Product Information - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of AKI, a condition that can lead to severe health consequences if not treated promptly [3] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier interventions and tailored management strategies [3] Company Facilities and Stock Information - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [4]